Liothyronine Sodium 55-06-1 — China API Manufacturer | EP USP R&D to Production

China Manufacturing Landscape for Liothyronine Sodium

Liothyronine Sodium (CAS 55-06-1) is the sodium salt of the biologically active thyroid hormone triiodothyronine (T3), used therapeutically in the treatment of hypothyroidism, myxedema coma, and thyroid suppression testing. With faster onset of action than levothyroxine, Liothyronine Sodium serves a distinct clinical niche and is an essential component of combination thyroid replacement therapies. China has developed specialized production capabilities for this potent thyroid hormone API, and our production facility supplies pharmaceutical formulators and compounding pharmacies worldwide with consistent, pharmacopeial-quality material.

Manufacturing Liothyronine Sodium requires exceptional precision in both synthesis and quality control, given the compound’s high potency and the narrow therapeutic window of thyroid hormone preparations. Our facility brings together deep expertise in iodinated amino acid chemistry, advanced purification technology, and rigorous quality systems purpose-built for this demanding product category.

Manufacturing Process & Facility Overview

Liothyronine Sodium production at our facility involves the selective triiodination of L-thyronine to produce the 3,5,3′-triiodo isomer, followed by controlled sodium salt formation and crystallization. The iodination chemistry is conducted under carefully optimized conditions in dedicated glass-lined reactors with real-time monitoring of reaction progress by HPLC sampling. Process parameters including temperature, iodine stoichiometry, and reaction time are precisely controlled to maximize selectivity for the triiodo product while minimizing tetraiodo (thyroxine) and diiodo impurity formation.

Downstream processing includes chromatographic purification using ion-exchange and reverse-phase columns for isomer separation, controlled crystallization for consistent salt form and hydration state, and gentle drying under reduced temperature and light-protected conditions. The manufacturing suite features dedicated light-shielded processing areas, inert atmosphere handling capability, and containment controls appropriate for high-potency API production. All operations are conducted under pharmaceutical quality controls with validated process controls and complete batch documentation.

Quality Standards & Multi-Pharmacopeial Compliance

Our Liothyronine Sodium API complies with European Pharmacopoeia (EP) and United States Pharmacopeia (USP) monograph requirements. The analytical control strategy includes assay by validated HPLC method (purity ≥95.0%), identification by UV spectroscopy, IR spectroscopy, and HPLC retention time, related substances analysis with specific limits for levothyroxine (T4) and diiodothyronine content, specific optical rotation measurement, sodium content determination, water content by Karl Fischer, and heavy metals testing by ICP-MS.

Enhanced controls for this high-potency, narrow-therapeutic-index API include tightened assay specifications, complete forced degradation studies confirming the stability-indicating nature of methods, and extended stability monitoring under ICH conditions with tight trending analysis. The QC laboratory maintains validated chiral HPLC methods and complete reference standard collections for all known iodothyronine related substances.

Regulatory Documentation & Export Support

Complete regulatory documentation is available to support customer drug registrations for Liothyronine Sodium formulations worldwide. Our documentation package includes Drug Master File (DMF) references, detailed impurity profile documentation with structural elucidation data, ICH-compliant stability data packages covering long-term, accelerated, and photostability conditions, process validation reports, and full analytical method validation documentation per ICH Q2(R1). Standard shipment documentation includes batch Certificates of Analysis, MSDS/SDS, and Certificates of Origin.

Our regulatory team has specific expertise in thyroid hormone API regulatory requirements and provides responsive technical support throughout customer filing and post-approval lifecycles across global markets.

Packaging & Global Logistics

Liothyronine Sodium is packaged in amber Type I glass bottles with PTFE-lined closures, sealed under nitrogen atmosphere with molecular sieve desiccant, and enclosed in secondary light-protective containers. Standard packaging units include 25 g, 100 g, 500 g, and 1 kg configurations. All packaging is conducted under controlled light and humidity conditions in a dedicated packaging suite to ensure maximum product stability.

Temperature-controlled shipping (2-8°C) is standard for all Liothyronine Sodium shipments to protect against thermal degradation during transit. We coordinate international logistics through specialized pharmaceutical freight providers, offering FOB, CIF, and DDP Incoterms. Air freight with cold chain management is the primary shipping mode, with delivery within 3-5 business days to most global destinations.

Competitive Pricing & Supply Reliability

Our dedicated thyroid hormone manufacturing platform enables efficient production of Liothyronine Sodium at competitive competitive pricing. We offer flexible pricing structures for development quantities, clinical trial supply, and commercial-scale procurement, with volume-based discounts and annual contract options providing cost predictability for procurement teams. Our pricing reflects the direct manufacturer advantage without distributor or trading company margins.

Supply reliability is maintained through coordinated production planning, strategic intermediate inventory management, and careful raw material procurement. Our thyroid hormone API production track record demonstrates consistent quality and on-time delivery performance exceeding 96%, with dedicated account managers ensuring proactive communication and responsive order management.

Liothyronine Sodium Technical Specifications